BPG is committed to discovery and dissemination of knowledge
Correspondence
Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Hepatol. Aug 27, 2026; 18(8): 117382
Published online Aug 27, 2026. doi: 10.4254/wjh.117382
Letter to the Editor: Natural product intervention in metabolic dysfunction-associated steatotic liver disease: From allyl isothiocyanate to signaling networks
Rui Tian, Yi-Xin Wu, Jie-Yu Guo, Xing-Zhen Chen, Jing-Feng Tang, Ce-Fan Zhou
Rui Tian, Jie-Yu Guo, Jing-Feng Tang, Ce-Fan Zhou, School of Life and Health Sciences, Institute of Biomedical Research, National “111” Center for Cellular Regulation and Molecular Pharmaceutics, Key Laboratory of Fermentation Engineering (Ministry of Education), Hubei University of Technology, Wuhan 430068, Hubei Province, China
Rui Tian, College of Biological and Food Engineering, Hubei Minzu University, Enshi 445000, Hubei Province, China
Yi-Xin Wu, School of Life and Health Sciences, Hubei University of Technology, Wuhan 430068, Hubei Province, China
Xing-Zhen Chen, Department of Physiology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton AB T6G 2R3, Canada
Author contributions: Tian R prepared the original draft; Zhou CF contributed to the conceptualization, writing, review, and editing of the manuscript; Tian R, Wu YX, Zhou CF, and Tang JF collaboratively drafted the manuscript; Guo JY and Chen XZ provided some valuable opinions, and all authors have reviewed and approved the final version of the manuscript.
AI contribution statement: DeepL software was used for language polishing. The main text of the manuscript was not generated by AI. We did not use any AI tool to participate in the study design or interpretation of the results. No images in the manuscript were generated by AI.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Corresponding author: Ce-Fan Zhou, PhD, Professor, School of Life and Health Sciences, Institute of Biomedical Research, National “111” Center for Cellular Regulation and Molecular Pharmaceutics, Key Laboratory of Fermentation Engineering (Ministry of Education), Hubei University of Technology, No. 28 Nanli Road, Wuhan 430068, Hubei Province, China. cefan@hbut.edu.cn
Received: December 8, 2025
Revised: December 25, 2025
Accepted: February 5, 2026
Published online: August 27, 2026
Processing time: 255 Days and 18.6 Hours
Core Tip

Core Tip: This comment highlights that allyl isothiocyanate (AITC) exemplifies the principle of multi-target natural product therapy for metabolic dysfunction-associated steatotic liver disease. In addition to the novel vitamin D receptor/hepatocyte nuclear factor 4 alpha pathway identified by Gao et al, we integrate this axis with established AITC targets, such as sirtuin 1/AMP-activated protein kinase and nuclear factor erythroid 2-related factor 2, to construct a multi-signaling network. This network collectively reprograms lipid metabolism, insulin sensitivity, and oxidative stress. Future research must validate this integrative mechanism in vivo and leverage systems biology to advance AITC as a precise, network-based therapeutic strategy.

Write to the Help Desk